RhumbLine Advisers
TRDA icon

RhumbLine Advisers’s Entrada Therapeutics TRDA Stock Holding History

RhumbLine Advisers’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$270K Buy
36,743
+805
+2% +$7.72K ﹤0.01% 3136
2026
Q1 		$454K Sell
35,938
-285
-0.8% -$3.27K ﹤0.01% 2673
2025
Q4 		$372K Sell
36,223
-3,205
-8% -$27K ﹤0.01% 2845
2025
Q3 		$229K Buy
39,428
+333
+0.9% +$1.95K ﹤0.01% 3157
2025
Q2 		$263K Buy
39,095
+2,982
+8% +$24K ﹤0.01% 3078
2025
Q1 		$326K Sell
36,113
-618
-2% -$7.7K ﹤0.01% 2840
2024
Q4 		$635K Buy
36,731
+433
+1% +$7.84K ﹤0.01% 2517
2024
Q3 		$580K Sell
36,298
-642
-2% -$10.1K ﹤0.01% 2601
2024
Q2 		$526K Buy
36,940
+7,452
+25% +$106K ﹤0.01% 2646
2024
Q1 		$418K Buy
29,488
+996
+3% +$14.1K ﹤0.01% 2778
2023
Q4 		$430K Buy
28,492
+2,043
+8% +$30.3K ﹤0.01% 2755
2023
Q3 		$418K Buy
26,449
+2,230
+9% +$35.1K ﹤0.01% 2717
2023
Q2 		$367K Buy
+24,219
New +$334K ﹤0.01% 2885

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

RhumbLine Advisers's TRDA Position: Q2 2026 in Review

RhumbLine Advisers increased its Entrada Therapeutics (TRDA) stake by 2.2% in Q2 2026, buying an estimated $7.72K and bringing the position to 36,743 shares worth $270K. The position accounts for ﹤0.01% of the portfolio, ranked #3136.

RhumbLine Advisers first reported a position in TRDA in Q2 2023 and has held it in 13 quarters since. The position peaked at $635K in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • RhumbLine Advisers held 36,743 shares of Entrada Therapeutics worth $270K as of Q2 2026.
  • RhumbLine Advisers bought 805 Entrada Therapeutics shares in Q2 2026, an estimated $7.72K.
  • Entrada Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3136 holding.
  • RhumbLine Advisers first reported a position in Entrada Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Entrada Therapeutics position peaked at $635K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.